# First-in-human Single Agent Study of SAR442085 in Relapsed or Refractory Multiple Myeloma

> **NCT04000282** · PHASE1 · COMPLETED · sponsor: **Sanofi** · enrollment: 37 (actual)

## Conditions studied

- Plasma Cell Myeloma

## Interventions

- **DRUG:** SAR442085

## Key facts

- **NCT ID:** NCT04000282
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-08-19
- **Primary completion:** 2022-08-29
- **Final completion:** 2023-09-04
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2025-09-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04000282

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04000282, "First-in-human Single Agent Study of SAR442085 in Relapsed or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04000282. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*